Clinical-stage biopharmaceutical company Apollomics today announced the completion of its business combination with Maxpro Capital Acquisition.
Apollomics’ shares and warrants began trading today on the Nasdaq under the symbols APLM and APLMW.
The merger was approved by Maxpro’s shareholders March 20, along with a $23.65 million PIPE. The SPAc disclosed after the vote that 10,270,060 shares were redeemed, which essentially wiped out Maxpro’s $105 million cash in trust. However, last month the SPAC secured the PIPE subscriptions, which were more than enough to cover the $20 million minimum to close the deal.
Apollomics is developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers. Read more.
